Lysine-based cluster mannosides that inhibit ligand binding to the human mannose receptor at nanomolar concentration

被引:69
作者
Biessen, EAL [1 ]
Noorman, F [1 ]
vanTeijlingen, ME [1 ]
Kuiper, J [1 ]
BarrettBergshoeff, M [1 ]
Bijsterbosch, MK [1 ]
Rijken, DC [1 ]
vanBerkel, TJC [1 ]
机构
[1] TNO PREVENT & HLTH,GAUBIUS LAB,NL-2301 CE LEIDEN,NETHERLANDS
关键词
D O I
10.1074/jbc.271.45.28024
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In search of synthetic high affinity ligands for the mannose receptor, we synthesized a series of lysine-based oligomannosides containing two (M(2)L) to six (M(6)L(5)) terminal alpha-D-mannose groups that are connected with the backbone by flexible elongated spacers (16 Angstrom). The synthesized cluster mannosides were all able to displace binding of biotinylated ribonuclease B and tissue-type plasminogen activator to isolated human mannose receptor, The affinity of these cluster mannosides for the mannose receptor was continuously enhanced from 18-23 mu M to 0.5-2.6 nM, with mannose valencies increasing from two to six. On average, expansion of the cluster mannoside with an additional alpha-D-mannose group resulted in a 10-fold increase in its affinity for the mannose receptor. M(3)L(2) to M(6)L(5) displayed negative cooperative inhibition of ligand binding to the mannose receptor, suggesting that binding of these mannosides involves multiple binding sites. The nanomolar affinity of the most potent ligand, the hexamannoside M(6)L(5) makes it the most potent synthetic cluster mannoside for the mannose receptor yet developed. As a result of its high affinity and accessible synthesis, M(6)L(5) not only is a powerful tool to study the mechanism of ligand binding by the mannose receptor, but it is also a promising targeting device to accomplish cell-specific delivery of genes and drugs to liver endothelial cells or macrophages in bone marrow, lungs, spleen, and atherosclerotic plaques.
引用
收藏
页码:28024 / 28030
页数:7
相关论文
共 33 条
[1]   LIGAND SIZE IS A MAJOR DETERMINANT OF HIGH-AFFINITY BINDING OF FUCOSE-EXPOSING AND GALACTOSE-EXPOSING (LIPO)PROTEINS BY THE HEPATIC FUCOSE RECEPTOR [J].
BIESSEN, EAL ;
BAKKEREN, HF ;
BEUTING, DM ;
KUIPER, J ;
VANBERKEL, TJC .
BIOCHEMICAL JOURNAL, 1994, 299 :291-296
[2]   SYNTHESIS OF CLUSTER GALACTOSIDES WITH HIGH-AFFINITY FOR THE HEPATIC ASIALOGLYCOPROTEIN RECEPTOR [J].
BIESSEN, EAL ;
BEUTING, DM ;
ROELEN, HCPF ;
VANDEMAREL, GA ;
VANBOOM, JH ;
VANBERKEL, TJC .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (09) :1538-1546
[3]   EVIDENCE FOR THE EXISTENCE OF AT LEAST 2 DIFFERENT BINDING-SITES FOR 5HT-REUPTAKE INHIBITORS WITHIN THE 5HT-REUPTAKE SYSTEM FROM HUMAN-PLATELETS [J].
BIESSEN, EAL ;
NORDER, JA ;
HORN, AS ;
ROBILLARD, GT .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (20) :3959-3966
[4]  
BIESSEN EAL, 1996, CIRCULATION, V92, P692
[5]   SELECTIVE-INHIBITION BY MONOSACCHARIDES OF TUMOR-CELL CYTO-TOXICITY MEDIATED BY MOUSE MACROPHAGES, MACROPHAGE-LIKE CELL-LINES, AND NATURAL-KILLER CELLS [J].
BRUNDA, MJ ;
WILTROUT, RH ;
HOLDEN, HT ;
VARESIO, L .
INTERNATIONAL JOURNAL OF CANCER, 1983, 31 (03) :373-379
[6]  
DERIJKE YB, 1992, J LIPID RES, V33, P1315
[7]   MURAMYL DIPEPTIDE BOUND TO POLY-L-LYSINE SUBSTITUTED WITH MANNOSE AND GLUCONOYL RESIDUES AS MACROPHAGE ACTIVATORS [J].
DERRIEN, D ;
MIDOUX, P ;
PETIT, C ;
NEGRE, E ;
MAYER, R ;
MONSIGNY, M ;
ROCHE, AC .
GLYCOCONJUGATE JOURNAL, 1989, 6 (02) :241-255
[8]   UPTAKE OF PNEUMOCYSTIS-CARINII MEDIATED BY THE MACROPHAGE MANNOSE RECEPTOR [J].
EZEKOWITZ, RAB ;
WILLIAMS, DJ ;
KOZIEL, H ;
ARMSTRONG, MYK ;
WARNER, A ;
RICHARDS, FF ;
ROSE, RM .
NATURE, 1991, 351 (6322) :155-158
[9]   MOLECULAR CHARACTERIZATION OF THE HUMAN MACROPHAGE MANNOSE RECEPTOR - DEMONSTRATION OF MULTIPLE CARBOHYDRATE RECOGNITION-LIKE DOMAINS AND PHAGOCYTOSIS OF YEASTS IN COS-1 CELLS [J].
EZEKOWITZ, RAB ;
SASTRY, K ;
BAILLY, P ;
WARNER, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (06) :1785-1794
[10]  
FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0